Zuellig Pharma enters a partnership agreement with Luye Pharma Group, an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The partnership will give Zuellig Pharma exclusive distribution and marketing rights to the central nervous system (CNS) drugs Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in Hong Kong.

An online signing ceremony was held in end May as part of a mental health awareness initiative “We Care About Mental Health”, marking the start of the new partnerships. Mental illnesses such as schizophrenia, bipolar disorder, depression, and anxiety place a considerable burden on global public health and the global economy. Aside from causing a serious negative social and emotional impact to sufferers and their loved ones, they also place a huge financial strain on society.

With quetiapine recommended as the preferred treatment for schizophrenia and bipolar disorder by authorized guidelines on diagnosis and treatment, the new distribution and marketing partnerships come as good news for both patients and the public.

“Zuellig Pharma has a comprehensive commercial platform as well as a wealth of knowledge and experience in CNS therapeutics in the Hong Kong market. The current pandemic has negatively affected many people’s mental health and created new barriers for those already suffering with this condition. We look forward to working closely with Luye Pharma on this timely partnership which is also very much in line with our overall mission to make healthcare more accessible in the region,” said Andi Umbricht, Chief Executive Zuellig Pharma Hong Kong.

As part of the “We Care About Mental Health” initiative, Zuellig Pharma together with Luye Pharma has committed to organising a series of online and offline lectures hosted by expert key opinion leaders in the field of mental health, helping to educate the public and further raise awareness of matters related to mental illness.

“Mental health is a serious global public health challenge that requires a sustained and united response from us all”, said Andy Siow, APAC Regional Director of Luye Pharma International. “By partnering with outstanding organizations in the region, we are confident that the ‘We Care About Mental Health’ initiative will help to increase understanding and awareness of mental health issues. It will also provide insights on the available treatment options and emphasize how important it is for sufferers to seek treatment.”